Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL67441 | 0.91 | ALDH1A1 (0.45) | ALDH1A1TSHR | |
| Ether SCHEMBL2591410 | 0.90 | ALDH1A1 (0.36) | ALDH1A1 | |
| Ether SCHEMBL11667411 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHR | |
| Ether SCHEMBL3841375 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHR | |
| Ether SCHEMBL21722990 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| Ether SCHEMBL626792 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| Ether SCHEMBL4702561 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 | |
| Ether SCHEMBL27914150 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Ether SCHEMBL2582345 | 0.78 | — | — | |
| Ether SCHEMBL1462917 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| US-20210322785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | THERAGENICS CORPORATION | 2021-10-21 | — | — | US | disclosed |
| EP-3893785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | C.P. Medical Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | C.P. MEDICAL CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113226211-A | Compositions and methods for treating wounds | CP医疗公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20140302051-A1 | Biocompatible Hydrogel Polymer Formulations for the Controlled Delivery of Biomolecules | MEDICUS BIOSCIENCES, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014153004-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271528-A1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | MEDICUS BIOSCIENCES LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140248231-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2708224-A1 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | Medicus Biosciences LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | ALDH1A1 297/4885TSHR 1883/4885 |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | HMGB1, HDGF, CRYAA | ALDH1A1 661/4885TSHR 2909/4885 |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | ALDH1A2, RB1, UACA | ALDH1A1 297/4885TSHR 1883/4885 |
| US-20140302051-A1 | Biocompatible Hydrogel Polymer Formulations for the Controlled Delivery of Biomolecules | HMGB1, HDGF, CRYAA | ALDH1A1 661/4885TSHR 2909/4885 |
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | ALDH1A1 113/4885TSHR 4398/4885 |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | ALDH1A1 84/4885TSHR 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.